Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics Tobira Therapeutics Tobira Therapeutics

Tobira Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies that address important and unmet medical needs in infectious diseases, with a current focus on HIV/AIDS. At Tobira, we are committed to creating value by building a world-class team, accelerating the development of our lead product candidate and expanding our pipeline through acquisitions and alliances.

Tobira Therapeutics
Tobira Therapeutics For more information on the Phase 2b study of cenicriviroc, click here.
Tobira Therapeutics
Tobira Therapeutics Join The Tobira Email List
Tobira Therapeutics
 

TOBIRA NEWS

4.5.12
Antoun Nabhan, JD, Joins Tobira Therapeutics Leadership Team

3.7.12
Pharmacokinetics (PK) of Cenicriviroc (CVC) following 100 or 200 MG Once-Daily Dosing with Open-label Tenofovir/Emtricitabine (TDF/FTC) in HIV-1-Infected Subjects Enrolled in a Phase 2b Study

Tobira Therapeutics
Tobira Therapeutics
  Digital Endeavor Websites